Institut National De La Sante Et De La Recherche Medicale

Other

Assistance Publique-hopitaux De Paris

UniversitÉ Paris Descartes

Université Paris Diderot-Paris 7

Université Pierre Et Marie Curie - Upmc

Sorbonne Université

Inserm

Pepkon

Pierre Launay

Philippe Karoyan

Santos A Susin

Helene Merle-Beral

Renato Monteiro

Benoît Pasquier

Ulrich Blank

Marc Benhamou

Marina Pretolani

Hélène Merle-Beral

Benoit Pasquier

The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Method and pharmaceutical composition for use in the treatment of cancer

The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

The invention relates to the use of a monovalent antibody fragment directed against the EC2 domain of the Fc&#x3b1;RI receptor for the treatment of inflammatory diseases.

Monovalent ligand of the Fc&#x3b1;RI receptor as an anti-inflammatory agent

Growing community of inventors

Paris, France

Pierre Launay